Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Rasche, M; von Neuhoff, C; Dworzak, M; Bourquin, J-P; Bradtke, J; Göhring, G; Escherich, G; Fleischhack, G; Graf, N; Gruhn, B; Haas, O A; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Stackelberg, A; Tchinda, J; Zemanova, Z; Thiede, C; von Neuhoff, N; Zimmermann, M; Creutzig, U; Reinhardt, D (2017). Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. Leukemia, 31(12):2807-2814.

Peirs, S; Frismantas, V; Matthijssens, F; Van Loocke, W; Pieters, T; Vandamme, N; Lintermans, B; Dobay, M P; Berx, G; Poppe, B; Goossens, S; Bornhauser, B C; Bourquin, J-P; Van Vlierberghe, P (2017). Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia, 31(10):2037-2047.

Dafflon, C; Craig, V J; Méreau, H; Gräsel, J; Schacher Engstler, B; Hoffman, G; Nigsch, F; Gaulis, S; Barys, L; Ito, M; Aguadé-Gorgorió, J; Bornhauser, B; Bourquin, J-P; Proske, A; Stork-Fux, C; Murakami, M; Sellers, W R; Hofmann, F; Schwaller, J; Tiedt, R (2017). Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Leukemia, 31(6):1269-1277.

Creutzig, U; Dworzak, M N; Zimmermann, M; Bourquin, J-P; Gruhn, B; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Stackelberg, A V; Starý, J; Reinhardt, D (2015). Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival. Leukemia, 29(11):2260-2263.

Eckert, C; Hagedorn, N; Sramkova, L; Mann, G; Panzer-Grümayer, R; Peters, C; Bourquin, J-P; Klingebiel, T; Borkhardt, A; Cario, G; Alten, J; Escherich, G; Astrahantseff, K; Seeger, K; Henze, G; von Stackelberg, A (2015). Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia, 29(8):1648-1655.

Creutzig, U; Dworzak, M; Zimmermann, M; Bourquin, J-P; Gruhn, B; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; von Stackelberg, A; Stray, J; Reinhardt, D (2015). Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. Klinische Pädiatrie, 227(3):116-122.

Malinge, S; Ragu, C; Della-Valle, V; Pisani, D; Constantinescu, S N; Perez, C; Villeval, J-l; Reinhardt, D; Landman-Parker, J; Michaux, L; Dastugue, N; Baruchel, A; Vainchenker, W; Bourquin, J-P; Penard-Lacronique, V; Bernard, O A (2008). Activating mutations in human acute megakaryoblastic leukemia. Blood, 112(10):4220-4226.

Bercovich, D; Ganmore, I; Scott, L M; Wainreb, G; Birger, Y; Elimelech, A; Shochat, C; Cazzaniga, G; Biondi, A; Basso, G; Cario, G; Schrappe, M; Stanulla, M; Strehl, S; Haas, O; Mann, G; Binder, V; Borkhardt, A; Kempski, H; Trka, J; Bielorei, B; Avigad, S; Stark, B; Smith, O; Dastugue, N; Bourquin, J-P; Tal, N B; Green, A R; Izraeli, S (2008). Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 372(9648):1484-1492.

Moosmann, P; Georgiev, O; Le Douarin, B; Bourquin, J-P; Schaffner, W (1996). Transcriptional Repression by RING Finger Protein TIF1 That Interacts with the KRAB Repressor Domain of KOX1. Nucleic Acids Research, 24(24):4859-4867.

This list was generated on Wed Dec 19 17:34:03 2018 CET.